Later, they ascertained the use of the OC-46F2 recombinant antibody in combination with the tumor-targeted antibody-based immunocytokine L19-IL2, which targets a fibronectin isoform enriched in tumor neovasculature, for melanoma therapy. Here, FN1 is linked to neoplasm.